Wim van Putten

5.0k total citations · 2 hit papers
26 papers, 3.4k citations indexed

About

Wim van Putten is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Wim van Putten has authored 26 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Wim van Putten's work include Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Retinoids in leukemia and cellular processes (4 papers). Wim van Putten is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Retinoids in leukemia and cellular processes (4 papers). Wim van Putten collaborates with scholars based in Netherlands, Switzerland and Belgium. Wim van Putten's co-authors include Bob Löwenberg, Ruud Delwel, Peter J.M. Valk, Leo F. Verdonck, Claudia Erpelinck-Verschueren, Harry C. Schouten, Augustin Ferrant, Aloïs Gratwohl, Pieter Sonneveld and Charles J. Vecht and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Wim van Putten

26 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

2009 596 citations Bob Löwenberg, Gert J. Ossenkoppele et al. New England Journal of Medicine profile →
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

2010 578 citations María E. Figueroa, Sanne Lugthart et al. Cancer Cell profile →

Peers

Countries citing papers authored by Wim van Putten

Since Specialization

Citations

This map shows the geographic impact of Wim van Putten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim van Putten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim van Putten more than expected).

Fields of papers citing papers by Wim van Putten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim van Putten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim van Putten. The network helps show where Wim van Putten may publish in the future.

Co-authorship network of co-authors of Wim van Putten

This figure shows the co-authorship network connecting the top 25 collaborators of Wim van Putten. A scholar is included among the top collaborators of Wim van Putten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim van Putten. Wim van Putten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission 2014 ·Blood ·Jurjen Versluis, (unknown), Wim van Putten, Jakob Passweg, Johan Maertens, Bart J. Biemond, Harry C. Schouten, Thomas Pabst, Bob Löwenberg, Gert J. Ossenkoppele, Edo Vellenga, Jan J. Cornelissen	1
2	Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine 2012 ·Blood ·Thomas Pabst, Edo Vellenga, Wim van Putten, Harry C. Schouten, Carlos Graux, Marie‐Christiane Vekemans, Bart J. Biemond, (unknown), Jakob Passweg, Leo F. Verdonck, (unknown), Matthias Theobald, E Jacky, Mario Bargetzi, Johan Maertens, Gert J. Ossenkoppele, Bob Löwenberg	65
3	Autologous peripheral blood stem cell transplantation for acute myeloid leukemia 2011 ·Blood ·Edo Vellenga, Wim van Putten, Gert J. Ossenkoppele, Leo F. Verdonck, Matthias Theobald, Jan J. Cornelissen, Peter C. Huijgens, Johan Maertens, Aloïs Gratwohl, Ron Schaafsma, Urs Schanz, Carlos Graux, Harry C. Schouten, Augustin Ferrant, Mario Bargetzi, Martin F. Fey, Bob Löwenberg	85
4	Cytarabine Dose for Acute Myeloid Leukemia 2011 ·New England Journal of Medicine ·Bob Löwenberg, Thomas Pabst, Edo Vellenga, Wim van Putten, Harry C. Schouten, Carlos Graux, Augustin Ferrant, Pieter Sonneveld, Bart J. Biemond, Aloïs Gratwohl, Georgine E. de Greef, Leo F. Verdonck, M Schaafsma, Michael Gregor, Matthias Theobald, Urs Schanz, Johan Maertens, Gert J. Ossenkoppele	276
5	Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial 2011 ·Blood ·Christian H. Geisler, (unknown), Wim van Putten, Jesper Jurlander, Jan Walewski, Geir E. Tjønnfjord, Maija Itälä‐Remes, Eva Kimby, Tomáš Kozák, Aaron Polliack, Shulamiet Wittebol, (unknown), Marinus H. J. van Oers	10
6	DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia breakdown → 2010 ·Cancer Cell ·María E. Figueroa, Sanne Lugthart, Yushan Li, Claudia Erpelinck-Verschueren, Xutao Deng, Paul J. Christos, Elizabeth D. Schifano, James G. Booth, Wim van Putten, Lucy Skrabanek, Fabien Campagne, Madhu Mazumdar, John M. Greally, Peter J.M. Valk, Bob Löwenberg, Ruud Delwel, Ari Melnick	578
7	Autologous Blood Stem Cell Transplantation Results In Better Relapse-Free Survival Than Consolidation Chemotherapy: Results of a HOVON/SAKK Phase III Trial In 519 AML Patients In First Complete Remission 2010 ·Blood ·Edo Vellenga, Wim van Putten, Gert J. Ossenkoppele, Martin F. Fey, Jürgen Kuball, Matthias Theobald, Jan J. Cornelissen, Peter C. Huijgens, Johan Maertens, Aloïs Gratwohl, Martyn Ronald Schaafsma, Markus G. Manz, Carlos Graux, Bob Löwenberg	1
8	High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia breakdown → 2009 ·New England Journal of Medicine ·Bob Löwenberg, Gert J. Ossenkoppele, Wim van Putten, Harry C. Schouten, Carlos Graux, Augustin Ferrant, Pieter Sonneveld, Johan Maertens, Mojca Jongen‐Lavrencic, Marie von Lilienfeld‐Toal, Bart J. Biemond, Edo Vellenga, Marinus van Marwijk Kooy, Leo F. Verdonck, Joachim Beck, Hartmut Döhner, Aloïs Gratwohl, Thomas Pabst, Gregor Verhoef	596
9	Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma 2008 ·Journal of Clinical Oncology ·Franck Morschhauser, John Radford, Achiel Van Hoof, Umberto Vitolo, Pierre Soubeyran, Hervé Tilly, Peter C. Huijgens, Arne Kolstad, Francesco d’Amore, Marcos González, Mario Petrini, Catherine Sebban, Pier Luigi Zinzani, Marinus H. J. van Oers, Wim van Putten, A. Bischof-Delaloye, A. Z. S. Rohatiner, Gilles Salles, Jens Kuhlmann, Anton Hagenbeek	314
10	Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1 2008 ·Cytometry Part B Clinical Cytometry ·Rik A. Brooimans, Jaco Kraan, Wim van Putten, Jan J. Cornelissen, Bob Löwenberg, J.W. Gratama	37
11	Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups. 2005 ·Blood ·Pieter Sonneveld, Wim van Putten, Harald Holte, Douwe H. Biesma, Marinus van Marwijk-Kooy, Mark H.H. Kramer, Pierre W. Wijermans, Monique Steijaert, Peter C. Huijgens, Mikael Eriksson	17
12	Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial 2004 ·Radiotherapy and Oncology ·P. Koper, Peter P. Jansen, Wim van Putten, Marjolein van Os, (unknown), Joos V. Lebesque, Peter C. Levendag	79
13	Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid Leukemia 2003 ·New England Journal of Medicine ·Bob Löwenberg, Wim van Putten, Matthias Theobald, J Gmür, Leo F. Verdonck, Pieter Sonneveld, Martin F. Fey, Harry C. Schouten, (unknown), Augustin Ferrant, Tibor Kovacsovics, Aloïs Gratwohl, Simon Daenen, Peter C. Huijgens, Marc Boogaerts	280
14	Classification And Regression Tree analysis (CART) with Stata 2002 ·RePEc: Research Papers in Economics ·Wim van Putten	3
15	Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy 2002 ·Journal of Neurology ·Peter Sillevis Smitt, (unknown), B. de Leeuw, Martin J. van den Bent, Wim van Putten, Herbert Hooijkaas, Charles J. Vecht	157
16	Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura—a single-institution experience with 189 patients 1999 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Jacoba van der Zee, Wim van Putten, Suresh Senan	83
17	Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery 1998 ·Journal of Neurology Neurosurgery & Psychiatry ·Marie‐Lise C. van Veelen, C. J. J. Avezaat, Johan M. Kros, Wim van Putten, Charles J. Vecht	175
18	113 Acute morbidity reduction using 3DCRT for prostate carcinoma; A randomised phase III study 1997 ·International Journal of Radiation OncologyBiologyPhysics ·P. Koper, Wim van Putten, J. Stroom, (unknown), Ben Heijmen, Arendjan Wijnmaalen, Peter P. Jansen, Patrick E. J. Hanssens, C. Griep, (unknown), (unknown), (unknown)	3
19	Autonomous Proliferation of Leukemic Cells in Vitro as a Determinant of Prognosis in Adult Acute Myeloid Leukemia 1993 ·New England Journal of Medicine ·(unknown), Wim van Putten, (unknown), (unknown), Valeria Santini	146
20	WAVELENGTH DEPENDENCE OF HEMATOPORPHYRIN DERIVATIVE PHOTODYNAMIC TREATMENT EFFECTS ON RAT EARS 1990 ·Photochemistry and Photobiology ·Willem M. Star, (unknown), Wim van Putten, (unknown)	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact